Creatv MicroTech’s Liquid Cell Biopsy and CAML cancer biomarker featured at AACR 2019
Mar 27, 2019
Creatv MicroTech, detecting and diagnosing cancer when it matters most, will present its latest findings on cancer diagnosis and treatment at the Annual American Association for Cancer Research (AACR) Meeting at Atlanta, Georgia, March 29 – April 3, 2019. Two posters will showcase the clinical utility of cancer-associated macrophagelike cells (CAMLs) biomarker.
Abstract No. 437 / 9: “Combining circulating stromal cells with cell free DNA for increased sensitivity in profiling oncogenic mutations and indicates highly aggressive non-small-cell lung cancer,” investigating the clinical potential of Circulogene’s Patient Mutation Load (PML) analysis from matched cfDNA, CAMLs, and tumor tissue to evaluate progression free survival (PFS) and overall survival (OS) in non-small-cell lung cancer (NSCLC).
Sunday March 31, 2019, 1:00 p.m. - 5:00 p.m.
Section 18, Poster Board 9
Presenter: Daniel L. Adams, Creatv MicroTech Inc.
Abstract No. 2915 / 3: “A circulating stromal cell subpopulation that accurately predicts resistance and progression in treatment naïve lung cancer patients receiving definitive radiotherapy,” investigating the use of CAMLs to monitor lung patient response to standardof-care chemo-radiation treatment.
Tuesday April 2, 2019, 8:00 AM. - 12:00 p.m.
Section 8, Poster Board 3
Presenter: Daniel L. Adams, Creatv MicroTech Inc.
Our presenting scientist will be available at the poster sessions and at the company’s exhibit booth #4007.
Cha-Mei Tang, Creatv’s President and CEO stated, “We are excited to present these results for the first time showing that our CAML biomarker provides quality genetic information on cancer patients, even those with early stage disease. Unlike ctDNA, CAMLs deliver many copies of whole DNA, enabling highly reliable mutation analysis.”
“Our second poster is on predicting treatment response. Currently during cancer therapy, oncologists rely on CT, MRI, and PET imaging to know whether the patient is responding to the therapy. Very often, however, these images do not provide a clear answer until well into the treatment regimen. If a patient is not responding, the oncologist may be able to provide alternative or additional treatment that may be more beneficial. We show that the CAML biomarker provides valuable information for monitoring treatment response sooner than the customary imaging cycles.”
About Creatv MicroTech
Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and to pharma companies to support drug development from its laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx® blood tests have an array of clinical applications including predicting response to a new therapy in 30 days, providing companion/complementary diagnostics such as PD-L1 using blood samples, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening.
Contact